Skip to main content
. 2016 Jun 12;2016:9697080. doi: 10.1155/2016/9697080

Figure 3.

Figure 3

Heterogeneity analyses. (a) MS (m/z) analyses of etanercept (red) and rituximab (black), (b) glycan heterogeneity by HILI-UPLC of Infinitam (blue) and the reference product (red), and (c) charge heterogeneity by cIEF of Infinitam (blue), reference product (red), and rituximab (black).